Comment
doi: 10.1200/JCO.2012.44.6237.
Epub 2012 Nov 19.
Improvement in progression-free survival in OCEANS bevacizumab arm: a critical point of view
- PMID: 23169499
- DOI: 10.1200/JCO.2012.44.6237
Item in Clipboard
Comment
Improvement in progression-free survival in OCEANS bevacizumab arm: a critical point of view
J Clin Oncol.
.
No abstract available
Comment on
-
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23. J Clin Oncol. 2012. PMID: 22529265 Free PMC article. Clinical Trial.
Similar articles
-
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23. J Clin Oncol. 2012. PMID: 22529265 Free PMC article. Clinical Trial.
-
Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.BioDrugs. 2013 Aug;27(4):375-92. doi: 10.1007/s40259-013-0043-4. BioDrugs. 2013. PMID: 23728884 Review.
-
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.Gynecol Oncol. 2013 Oct;131(1):21-6. doi: 10.1016/j.ygyno.2013.07.100. Epub 2013 Jul 29. Gynecol Oncol. 2013. PMID: 23906656 Free PMC article. Clinical Trial.
-
Controversy in treatment of advanced ovarian cancer.Lancet Oncol. 2013 Sep;14(10):920-1. doi: 10.1016/S1470-2045(13)70391-7. Lancet Oncol. 2013. PMID: 23993374 No abstract available.
-
Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.Gynecol Oncol. 2015 Jun;137(3):392-400. doi: 10.1016/j.ygyno.2015.03.008. Epub 2015 Mar 17. Gynecol Oncol. 2015. PMID: 25792179 Review.
Cited by
-
Current status of bevacizumab in advanced ovarian cancer.Onco Targets Ther. 2013 Jul 22;6:889-99. doi: 10.2147/OTT.S46301. Print 2013. Onco Targets Ther. 2013. PMID: 23901283 Free PMC article.
-
Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration.J Gynecol Oncol. 2014 Oct;25(4):355-6. doi: 10.3802/jgo.2014.25.4.355. J Gynecol Oncol. 2014. PMID: 25310036 Free PMC article. No abstract available.
-
Investigating molecular profiles of ovarian cancer: an update on cancer stem cells.J Cancer. 2014 Mar 16;5(5):301-10. doi: 10.7150/jca.8610. eCollection 2014. J Cancer. 2014. PMID: 24723972 Free PMC article. Review.
-
Bevacizumab in ovarian cancer: A critical review of phase III studies.Oncotarget. 2017 Feb 14;8(7):12389-12405. doi: 10.18632/oncotarget.13310. Oncotarget. 2017. PMID: 27852039 Free PMC article. Review.
-
Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach.J Exp Clin Cancer Res. 2013 Aug 1;32(1):48. doi: 10.1186/1756-9966-32-48. J Exp Clin Cancer Res. 2013. PMID: 23902592 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
